GSK targets late 2027 launch for Depemokimab ultra-long-acting biologic
UK pharmaceutical giant GSK is advancing Depemokimab, an ultra-long-acting biologic therapy, toward a late 2027 market entry. The drug represents GSK's push into extended-interval treatments that reduce dosing frequency for chronic conditions.
ViaNews Editorial Team (Europe)•